Skip to main content

MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

10 Dec 2015 Evaluate

Alembic Pharmaceuticals has informed about a press release dated December 09, 2015 titled ‘Rhizen Pharmaceuticals announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1398.00
Cipla 1416.00
Lupin 1999.00
Zydus Lifesciences 1200.00
View more..